Table 3. Inflammatory biomarkers in subgroup analysis of autoimmune diseases and suspected autoimmune diseases-related CCSVI.
| Variables | APS (n=18) | SS (n=8) | IgG4-related disease (n=7) | Decreased C3 (n=76) | Decreased C4 (n=38) | Increased ESR (n=21) | Increased IgG (n=10) | Increased IgE (n=5) | Positive RF (n=4) | P value |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | 49.61±3.75^ | 61.75±3.48 | 43.00±9.73^ | 57.17±1.49#^ | 53.71±2.75^ | 58.61±2.65^ | 58.90±5.62 | 47.00±6.17^ | 70.75±1.75 | 0.009 |
| Gender (M:F) | 8:10 | 3:5 | 1:6 | 40:36 | 23:15 | 4:17 | 2:8 | 4:1 | 2:2 | 0.021 |
| NLR on admission& | 1.81±0.16 | 2.20±0.36 | 1.48±0.12 | 1.80±0.09 | 1.76±0.12 | 1.97±0.24 | 1.74±0.17 | 1.81±0.45 | 1.70±0.16 | 0.865 |
| NLR at discharge | NR | 1.98±0.79 | 1.90±0.45 | 2.59±0.49 | 2.76±0.49 | 2.41±0.38 | NR | NR | NR | 0.350 |
| PLR on admission | 112.13±9.27 | 148.78±16.02 | 104.96±13.76 | 121.59±5.36 | 117.43± 7.57 | 123.45±6.41 | 108.23±8.73 | 139.56±25.72 | 116.68±8.80 | 0.472 |
| PLR at discharge& | NR | 143.48±21.89 | 99.46±4.44 | 126.27±16.43 | 151.60±12.82 | 121.41±29.79 | NR | NR | NR | 0.695 |
| RDW on admission (%) | 13.15±0.34 | 13.2±0.23 | 12.83±0.14 | 13.06±0.17 | 13.0±0.17 | 13.35±0.53 | 15.3±1.44 | 13.2±0.14 | 13.08±0.33 | 0.513 |
| RDW at discharge (%)& | NR | 12.77±0.27 | 12.90±0.29 | 12.69±0.13 | 12.62±0.12 | 15.52±1.72 | NR | NR | NR | 0.373 |
| IL-6 (pg/mL) | 4.66±1.26 | 8.72±5.42 | 5.80±2.13 | 4.82±0.90 | 4.99±1.67 | 4.75±1.02 | 5.30±1.29 | 2.66±0.66 | 3.57±0.81 | 0.291 |
| CRP (mg/L) | 2.44±0.22§ | 2.29±0.43 | 2.46±0.65§ | 1.78±0.10 | 1.89±0.16 | 4.39±0.76 | 3.30±0.85§ | 2.66±0.69 | 2.08±0.33 | <0.001 |
| NSE (ng/mL) | 12.70±0.47 | 14.75±1.58 | 14.97±2.35 | 12.57±0.79 | 11.58±0.61 | 12.82±0.37 | 11.58±0.61 | 12.57±0.79 | 13.39±1.01 | 0.536 |
&, the number of patients who had complete blood count (CBC) test at discharge (n=36); #, compared with group of APS, statistically significant at P<0.05; ^, compared with group of SS, statistically significant at P<0.05; §, compared with group of decreased C3, statistically significant at P<0.05. CCSVI, chronic cerebrospinal venous insufficiency; APS, antiphospholipid syndrome; SS, Sjögren’s syndrome; C3, complement 3; C4, complement 4; ESR, erythrocyte sedimentation rate; RF, rheumatic factor; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; RDW, red blood cell distribution width; IL-6, interleukin-6; CRP, C-reactive protein; NSE, neuron-specific enolase.